Last reviewed · How we verify
Solifenacin succinate treatment
Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions.
Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | Solifenacin succinate treatment |
|---|---|
| Also known as | VESIcare |
| Sponsor | Barrie Urology Associates |
| Drug class | Muscarinic M3 receptor antagonist |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing acetylcholine-induced contractions. This reduces urinary urgency and frequency, and increases bladder capacity. It is used to treat overactive bladder symptoms by suppressing the parasympathetic signaling that drives inappropriate bladder contractions.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Headache
Key clinical trials
- Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (PHASE4)
- Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (PHASE2)
- Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women (PHASE3)
- Mirabegron in Patients With Age-Related Macular Degeneration
- Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
- Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females (NA)
- Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) (PHASE4)
- Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solifenacin succinate treatment CI brief — competitive landscape report
- Solifenacin succinate treatment updates RSS · CI watch RSS
- Barrie Urology Associates portfolio CI